0000950103-16-010558.txt : 20160128 0000950103-16-010558.hdr.sgml : 20160128 20160128144220 ACCESSION NUMBER: 0000950103-16-010558 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160128 DATE AS OF CHANGE: 20160128 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PIERIS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001583648 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 300784346 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88917 FILM NUMBER: 161368112 BUSINESS ADDRESS: STREET 1: 255 STATE STREET STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 603-553-5803 MAIL ADDRESS: STREET 1: 255 STATE STREET STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Marika Inc. DATE OF NAME CHANGE: 20130805 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NOVO NORDISK A S CENTRAL INDEX KEY: 0000353278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 BUSINESS PHONE: 4544448888 MAIL ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NOVO NORDISK A/S DATE OF NAME CHANGE: 19900807 FORMER COMPANY: FORMER CONFORMED NAME: NOVO INDUSTRI A S /DENMARK/ DATE OF NAME CHANGE: 19890811 SC 13G 1 dp62943_sc13g.htm FORM SC 13G

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

PIERIS PHARMACEUTICALS, INC.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
720795103
(CUSIP Number)
 
June 24, 2015
(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

 

o Rule 13d-1(c)

 

x Rule 13d-1(d)

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Page 1 of 5
 

 

CUSIP No. 720795103 13G  
 
1.

NAMES OF REPORTING PERSONS

 

Novo Nordisk A/S

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o
    (b) o
     

3. SEC USE ONLY
   
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

The Kingdom of Denmark

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

2,051,802

6.

SHARED VOTING POWER

 

0

7.

SOLE DISPOSITIVE POWER

 

2,051,802

8.

SHARED DISPOSITIVE POWER

 

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,051,802

 

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
  o
11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.2% based on 39,759,530 outstanding common shares

 

12.

TYPE OF REPORTING PERSON*

 

CO

 

 

Page 2 of 5
 

 

Item 1(a). Name of Issuer:

 

Pieris Pharmaceuticals, Inc.

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

 

Lise-Meitner-Strasse 30

 

85354 Freising-Weihenstephan

 

Germany

 

Item 2(a). Name of Person Filing:

 

Novo Nordisk A/S

 

Item 2(b). Address of Principal Business Office or, if None, Residence:

 

Novo Allé

 

DK – 2880, Bagsvaerd

 

Denmark

 

Item 2(c). Citizenship:

 

The Kingdom of Demark

 

Item 2(d). Title of Class of Securities:

 

Common Stock

 

Item 2(e). CUSIP Number:

 

720795103

 

Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

 

(b)o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c)o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d)o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

 

(e)o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

(f)o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

(g)o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

(h)o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j)o A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);

 

(k)o Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

Page 3 of 5
 

Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

 

(a)Amount beneficially owned: 2,051,802

 

(b)Percent of class: 5.2% based on 39,759,530 outstanding common shares

 

(c)Number of shares as to which such person has:

 

  (i) Sole power to vote or to direct the vote:  See item 5 of cover page.
     
  (ii) Shared power to vote or to direct the vote:  See item 6 of cover page.
     
  (iii) Sole power to dispose or to direct the disposition of:  See item 7 of cover page.
     
  (iv) Shared power to dispose or to direct the disposition of:  See item 8 of cover page.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. o

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certifications.

 

Not applicable.

 

Page 4 of 5
 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

January 28, 2016
(Date)
 
/s/ Jesper Brandgaard
(Signature)
 
Jesper Brandgaard, Chief Financial Officer
(Name/Title)

 


Page 5 of 5